Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris A Ratsch

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2007
Long-term commitment to inflammation-seeking homing in CD4+ effector cellsSilke Jennrich, Boris A Ratsch, Alf Hamann, et al.
Seminars in Hematology|July 26, 2011
The use of microarray technologies in mantle cell lymphomaBoris A Ratsch, Michael Grau, Bernd Dörken, et al.
European Journal of Haematology|September 29, 2020
Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims databaseChristof Scheid, Igor W Blau, Leopold Sellner, et al.
Zeitschrift Fur Gastroenterologie|March 16, 2019
Perianal fistulas in adult patients with Crohn's disease in Germany - a retrospective cross-sectional analysis of claims data from German sickness fundsElena Georgiadou, Lena Fanter, Alina Brandes, et al.
Immunology|October 9, 2012
Differential regulation and impact of fucosyltransferase VII and core 2 β1,6-N-acetyl-glycosaminyltransferase for generation of E-selectin and P-selectin ligands in murine CD4+ T cellsMicha F Schroeter, Boris A Ratsch, Jeanette Lehmann, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|July 13, 2020
Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in GermanyEdin Basic, Mathias Kappel, Arpit Misra, et al.
Patient Preference and Adherence|December 7, 2018
Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?Thomas Wilke, Sabrina Mueller, Sabine Bauer, et al.
Molecular Immunology|June 11, 2014
Identification of two regulatory elements controlling Fucosyltransferase 7 transcription in murine CD4+ T cellsMatthias Pink, Boris A Ratsch, Maibritt Mardahl, et al.
Zeitschrift Fur Gastroenterologie|July 10, 2019
Real-world biologic treatment and associated cost in patients with inflammatory bowel diseaseAlina Brandes, Antje Groth, Fraence Gottschalk, et al.
Digestion|October 23, 2019
Persistence with Biologic Treatment in Patients with Inflammatory Bowel Disease: A German Claims Data AnalysisAntje Mevius, Alina Brandes, Fränce Hardtstock, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2007
Long-term commitment to inflammation-seeking homing in CD4+ effector cellsSilke Jennrich, Boris A Ratsch, Alf Hamann, et al.
Seminars in Hematology|July 26, 2011
The use of microarray technologies in mantle cell lymphomaBoris A Ratsch, Michael Grau, Bernd Dörken, et al.
European Journal of Haematology|September 29, 2020
Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims databaseChristof Scheid, Igor W Blau, Leopold Sellner, et al.
Zeitschrift Fur Gastroenterologie|March 16, 2019
Perianal fistulas in adult patients with Crohn's disease in Germany - a retrospective cross-sectional analysis of claims data from German sickness fundsElena Georgiadou, Lena Fanter, Alina Brandes, et al.
Immunology|October 9, 2012
Differential regulation and impact of fucosyltransferase VII and core 2 β1,6-N-acetyl-glycosaminyltransferase for generation of E-selectin and P-selectin ligands in murine CD4+ T cellsMicha F Schroeter, Boris A Ratsch, Jeanette Lehmann, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|July 13, 2020
Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in GermanyEdin Basic, Mathias Kappel, Arpit Misra, et al.
Patient Preference and Adherence|December 7, 2018
Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?Thomas Wilke, Sabrina Mueller, Sabine Bauer, et al.
Molecular Immunology|June 11, 2014
Identification of two regulatory elements controlling Fucosyltransferase 7 transcription in murine CD4+ T cellsMatthias Pink, Boris A Ratsch, Maibritt Mardahl, et al.
Zeitschrift Fur Gastroenterologie|July 10, 2019
Real-world biologic treatment and associated cost in patients with inflammatory bowel diseaseAlina Brandes, Antje Groth, Fraence Gottschalk, et al.
Digestion|October 23, 2019
Persistence with Biologic Treatment in Patients with Inflammatory Bowel Disease: A German Claims Data AnalysisAntje Mevius, Alina Brandes, Fränce Hardtstock, et al.
Pageof 2